Abstract:Background. There is a significant role for peroxisome proliferator-activated receptors (PPARs) in the development of cancer. Nevertheless, the role of PPARs-related genes in ovarian cancer (OC) remains unclear. Methods. The open-accessed data used for analysis were downloaded from The Cancer Genome Atlas database, which was analyzed using the R software. Results. In our study, we comprehensively investigated the PPAR target genes in OC, including their biological role. Meanwhile, a prognosis signature consisting of eight PPAR target genes was established, including apolipoprotein A-V, UDP glucuronosyltransferase 2 family, polypeptide B4, TSC22 domain family, member 1, growth hormone inducible transmembrane protein, renin, dedicator of cytokinesis 4, enoyl CoA hydratase 1, peroxisomal (ECH1), and angiopoietin-like 4, which showed a good prediction efficiency. A nomogram was constructed by combining the clinical feature and risk score. Immune infiltration and biological enrichment analysis were applied to investigate the difference between high- and low-risk patients. Immunotherapy analysis indicated that low-risk patients might respond better to immunotherapy. Drug sensitivity analysis indicated that high-risk patients might respond better to bleomycin, nilotinib, pazopanib, pyrimethamine, and vinorelbine, yet worse to cisplatin and gefitinib. Furthermore, the gene ECH1 was selected for further analysis. Conclusions. Our study identified a prognosis signature that could effectively indicates patients survival. Meanwhile, our study can provide the direction for future studies focused on the PPARs in OC.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the role of peroxisome proliferator - activated receptor (PPARs) - related genes in ovarian cancer (OC), especially their relationship with the prognosis of ovarian cancer and the tumor microenvironment. Although it is known that PPARs play an important role in the process of cancer development, their specific role in ovarian cancer remains unclear. Therefore, researchers hope to comprehensively analyze PPARs - targeted genes, identify genes related to the prognosis of ovarian cancer, and explore the role of these genes in the tumor microenvironment. Specifically, researchers address this problem through the following points: 1. **Data collection and processing**: Downloaded the expression profiles and clinical feature data of ovarian cancer patients from The Cancer Genome Atlas (TCGA) database, and used R software for data pre - processing and analysis. 2. **Biological difference analysis**: Used the ClusterProfiler tool for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to understand the biological functions of PPARs - targeted genes. 3. **Establishment of prognostic features**: Screened out genes closely related to patient survival through univariate Cox regression analysis, and then further screened and optimized variables using the least absolute shrinkage and selection operator (LASSO) regression algorithm. Finally, a prognostic feature composed of eight PPARs - targeted genes was determined through multivariate Cox regression analysis. 4. **Model evaluation**: Used Kaplan - Meier (KM) curves and receiver operating characteristic (ROC) curves to evaluate the performance of the prognostic model, and established a nomogram combining risk scores and clinical features. 5. **Immune infiltration and function analysis**: Used multiple algorithms (such as CIBERSORT, EPIC, MCP - counter, quanTIseq, TIMER and xCell) to quantify cell infiltration in the ovarian cancer tumor microenvironment, and carried out immune function analysis based on the single - sample gene set enrichment analysis (ssGSEA) algorithm. 6. **Immune therapy and drug sensitivity assessment**: Used the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm to assess patients' responses to immune therapy, and carried out drug sensitivity analysis based on the data in the Genomics of Drug Sensitivity in Cancer database. 7. **Biological enrichment analysis**: Further explored the biological differences between high - risk and low - risk patients through gene set enrichment analysis (GSEA). 8. **Further study of the ECH1 gene**: Paid special attention to the ECH1 gene, analyzed its expression in different patient groups and its relationship with immune cell infiltration and biological pathways. Through the above methods, researchers hope to provide new perspectives and potential therapeutic targets, and provide directions for the clinical application and future research of ovarian cancer.

Comprehensive Analysis Identifies the PPAR-Targeted Genes Associated with Ovarian Cancer Prognosis and Tumor Microenvironment

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer Via Integrated Bioinformatics Analysis.

Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer

Exploration of pyroptosis-associated prognostic gene signature and lncRNA regulatory network in ovarian cancer

Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer

Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.

Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis

Comprehensive Analysis of Purine-Metabolism-Related Gene Signature for Predicting Ovarian Cancer Prognosis, Immune Landscape, and Potential Treatment Options

Characteristics of Oxidative Phosphorylation-Related Subtypes and Construction of a Prognostic Signature in Ovarian Cancer

Construction of a PANoptosis-related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Ovarian Cancer

The Expression of PPAR Pathway-Related Genes Can Better Predict the Prognosis of Patients with Colon Adenocarcinoma

Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer

Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis

Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis

Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome

Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients

Identification of genes predicting chemoresistance and short survival in ovarian cancer

Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma

Integrated analysis of prognostic immune-related genes in the tumor microenvironment of ovarian cancer